IMAXIO S.A. news

Osivax, a clinical-stage biotech start’up focused on vaccines and based in Lyon (France), announces today the closing of a seed funding round of EUR 2.7 million.

Osivax was recently created as a spin-off of the R&D department of Imaxio, a biotech company also based in Lyon. The objectives of the spin-off are to enable Osivax to focus on the development of the R&D platform and Imaxio to accelerate the commercial development of its leptospirosis vaccine commercialized curr

Imaxio, a biotech company specializing in immunology announces today that it has signed a license agreement with the world-renowned German Cancer Research Center (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed.

It follows a 2-year evaluation of Imaxio’s IMX313P pro-immunogenic technology by DKFZ under a license option agreement. This evaluation has proven the ability of IMX313P to enhance the efficacy

Imaxio, a biotech company specializing in immunology, announces today that it has received scientific advice from the European Medicines Agency (EMA) for IMX836, its vaccine candidate dedicated to the prevention of influenza in humans.

This first scientific advice reinforces Imaxio’s plan to start, by early 2018, a phase I clinical trial involving IMX836.

Imaxio’s influenza vaccine candidate IMX836 is being developed as an add-on to seasonal vaccines, in order to i

Imaxio, a biotech company specializing in immunology announces today the sale of Trolovol® (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. The transaction was facilitated by CMC Consulting Group.

This sale is aligned with Imaxio’s willingness to refocus its business on vaccines. This is the result of several years of work by Imaxio’s teams, which have increased Trolovol®’s turnover since its

Imaxio, a biotech company specialising in immunology, announces today the execution of a license agreement with AJ Biologics, a Malaysian company dedicated to vaccine manufacturing and commercialization, as part of the company’s strategy to extend the distribution of Imaxio’s leptospirosis vaccine in Malaysia.

Imaxio is a French SME developing an early clinical stage pipeline of vaccine candidates based on its proprietary technology named IMX313, as well as commercialising

Imaxio, a biotech company specialized in immunology, announces today the execution of a collaboration agreement with Centre Léon Bérard, and the award of a grant, as part of the program “Proof of Concept CLARA” from the Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA), to finance the ORPhEE project.

The ORPhEE project, “non-antigen specific intratumoral immunostimulation”, is an initiative of both Imaxio and its partner Centre L&ea

Imaxio, a biotech company specialized in immunology, announces today having received from the USPTO (United States Patent and Trademark Office) notices of allowance for two of its latest patent applications.

Submitted in 2012 and 2013, and respectively entitled “Modified coiled-coil type proteins having improved properties” and “Influenza nucleoprotein vaccines”, these two patents offer additional cover on the American market to the new generation of Imaxio&rsq

Imaxio, a biotech company specialized in immunology, announces today that the results of its tuberculosis vaccine phase I clinical trial have been published in the journal Vaccine. The trial, which was conducted by the Jenner Institute at Oxford University (UK), has proved that the vaccine candidate (and thus IMX313, Imaxio’s antigen re-engineering technology) is safe in humans. The study was performed in the UK and was led by Prof. Helen McShane from the Jenner Institute at Oxford Univ

The Jenner Institute at Oxford University, together with partners Imaxio and GSK, has started a phase I clinical trial of a novel vaccine candidate aimed at blocking transmission of malaria.

Around half the world’s population is at risk of malaria and the disease led to an estimated 584,000 deaths in 2013. MosquirixTM, a malaria vaccine candidate developed by GSK, has just received a positive scientific opinion from the European Medicines Agency for use in young children. Mosqui

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded a funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project: “leveraging On t-cell immune resPonse To Improve influenza VACcines”.

The aim of the OPTIVAC project is to improve the efficacy of vaccines for seasonal influenza and current pandemics. To achieve this, it will develop a candidate v